Viking Therapeutics (VKTX) Receives Buy Rating from Maxim Group

Maxim Group reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a report released on Thursday. The firm currently has a $28.00 target price on the biotechnology company’s stock.

“Viking reported 3Q18 with a net loss of ($6.6M) and ended the period with $304M in cash. We have increased expenses going forward as the NASH program moves into later-stage development and additional programs like 0214 move into the clinic.”,” Maxim Group’s analyst commented.

A number of other equities analysts also recently commented on the company. HC Wainwright restated a buy rating and issued a $31.00 price objective on shares of Viking Therapeutics in a report on Thursday. BidaskClub cut Viking Therapeutics from a hold rating to a sell rating in a research report on Wednesday, October 3rd. William Blair reaffirmed a market perform rating on shares of Viking Therapeutics in a research report on Monday, October 1st. Raymond James set a $43.00 target price on Viking Therapeutics and gave the stock a buy rating in a research report on Wednesday, September 19th. Finally, Roth Capital upped their target price on Viking Therapeutics from $13.00 to $24.00 and gave the stock a buy rating in a research report on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $28.17.

NASDAQ:VKTX traded down $0.81 during mid-day trading on Thursday, reaching $12.33. The stock had a trading volume of 4,027,660 shares, compared to its average volume of 2,884,523. Viking Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $24.00. The company has a market capitalization of $833.44 million, a P/E ratio of -15.61 and a beta of 2.92.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. On average, equities analysts predict that Viking Therapeutics will post -0.44 earnings per share for the current year.

In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $19.15, for a total transaction of $5,034,171.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. FMR LLC bought a new stake in shares of Viking Therapeutics in the third quarter valued at approximately $125,858,000. Boxer Capital LLC boosted its position in shares of Viking Therapeutics by 17.7% in the second quarter. Boxer Capital LLC now owns 3,750,000 shares of the biotechnology company’s stock valued at $35,588,000 after acquiring an additional 564,000 shares during the period. BlackRock Inc. boosted its position in shares of Viking Therapeutics by 14.0% in the third quarter. BlackRock Inc. now owns 3,349,901 shares of the biotechnology company’s stock valued at $58,355,000 after acquiring an additional 411,256 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Viking Therapeutics in the second quarter valued at approximately $19,552,000. Finally, Millennium Management LLC boosted its position in shares of Viking Therapeutics by 99.1% in the first quarter. Millennium Management LLC now owns 1,399,370 shares of the biotechnology company’s stock valued at $6,115,000 after acquiring an additional 696,398 shares during the period. 53.56% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Featured Story: Google Finance Portfolio

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply